SteelPeak Wealth’s Lexicon Pharmaceuticals LXRX Stock Holding History

SteelPeak Wealth’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$34K	–	393
2020 Q4	$34K	Buy	+10,000	New	+$19.1K	﹤0.01%	319

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SteelPeak Wealth's LXRX Position: Q1 2021 in Review

SteelPeak Wealth sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2021, closing a stake of 10,000 shares — an estimated $34K sold.

SteelPeak Wealth first reported a position in LXRX in Q4 2020 and held it in 1 quarter. The position peaked at $34K in Q4 2020. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

SteelPeak Wealth reported no remaining Lexicon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
SteelPeak Wealth sold 10,000 Lexicon Pharmaceuticals shares in Q1 2021, an estimated $34K.
SteelPeak Wealth first reported a position in Lexicon Pharmaceuticals in Q4 2020 and held it in 1 quarter.
SteelPeak Wealth's Lexicon Pharmaceuticals position peaked at $34K in Q4 2020.
107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on SteelPeak Wealth's 13F filing for Q1 2021, filed 18 May 2021.